Showing results (111-120 of 143) with videos related to
Sort By:
Pageof 15
Oncology|June 12, 2023
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve FunctionAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Scientific Reports|January 3, 2025
Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinibHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.Journal of Gastroenterology|May 12, 2026
Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026Norio Akuta, Tomomi Kogiso, Kenichi Ikejima, et al.Liver International : Official Journal of the International Association for the Study of the Liver|September 19, 2025
Clinical Utility of a Prognostic Scoring System Based on LDH and CRP in HCC Patients Receiving Atezolizumab Plus BevacizumabKazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.Journal of Gastroenterology and Hepatology|January 23, 2025
Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab-Treated HCCTomomitsu Matono, Toshifumi Tada, Takashi Kumada, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 20, 2023
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter studyTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 12, 2026
Evidence-Based Clinical Practice Guidelines for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) 2026Norio Akuta, Tomomi Kogiso, Kenichi Ikejima, et al.Cancer Medicine|November 21, 2023
Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed-effects regression model approachTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.Liver International : Official Journal of the International Association for the Study of the Liver|October 4, 2023
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinomaToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Cancer Reports (Hoboken, N.J.)|April 5, 2024
Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinomaHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.Pageof 15